IP Library Granted Patent US 9,410,214
Granted Patent B2
US 9,410,214 · App. 14/214,062 · Granted Aug 9, 2016

Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme A derived compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,410,214
App. No.
14/214,062
Granted
Aug 9, 2016
Kind
B2
Abstract

Provided herein are compositions and methods for improved production of acetyl-CoA and acetyl-CoA derived compounds in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a phosphoketolase (PK), and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding a phosphotransacetylase (PTA). In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase. In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2. The compositions and methods described herein provide an efficient route for the heterologous production of acetyl-CoA-derived compounds, including but not limited to, isoprenoids, polyketides, and fatty acids.

Claims (42)

1. A genetically modified yeast host cell capable of producing an isoprenoid, acetyl-CoA or an acetyl-CoA derived compound, the genetically modified yeast host cell comprising:

(a) a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9);

(b) a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8); and

(c) a functional disruption of an endogenous glycerol-1-phosphatase enzyme (EC 3.1.3.21) that converts acetyl phosphate to acetate,

wherein the genetically modified yeast host cell produces an increased amount of an isoprenoid, acetyl-CoA or an acetyl-CoA derived compound compared to yeast cells which are not geneically modified in the same way.

2. The genetically modified yeast host cell of claim 1 , wherein the glycerol-1-phosphatase is selected from GPP1/RHR2, GPP2/HOR2, and homologues and variants thereof.

3. The genetically modified yeast host cell of claim 2 , wherein GPP1/RHR2, or a homologue or variant thereof, is functionally disrupted.

4. The genetically modified yeast host cell of claim 2 , wherein GPP2/HOR2, or a homologue or variant thereof, is functionally disrupted.

5. The genetically modified yeast host cell of claim 2 , wherein both GPP1/RHR2 and GPP2/HOR2, or both a homologue or variant of GPP1/RHR2 and a homologue or variant of GPP2/HOR2, are functionally disrupted.

6. The genetically modified yeast host cell of claim 1 , wherein the genetically modified host cell comprises one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway for making isopentenyl pyrophosphate.

7. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an NADH-using HMG-CoA reductase.

8. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an enzyme that condenses two molecules of acetyl-CoA to form acetoacetyl-CoA.

9. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA.

10. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an enzyme that converts HMG-CoA to mevalonate.

11. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate.

12. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate.

13. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway comprise an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate.

14. The genetically modified yeast host cell of claim 6 , wherein the one or more enzymes of the MEV pathway are selected from HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase and mevalonate pyrophosphate decarboxylase.

15. The genetically modified yeast host cell of claim 6 , wherein the host cell comprises a plurality of heterologous nucleic acids encoding all of the enzymes of the MEV pathway.

16. The genetically modified yeast host cell of claim 6 , wherein the one or more heterologous nucleic acids encoding one or more enzymes of the MEV pathway are under control of a single transcriptional regulator.

17. The genetically modified yeast host cell of claim 6 , wherein the one or more heterologous nucleic acids encoding one or more enzymes of the MEV pathway are under control of multiple heterologous transcriptional regulators.

18. The genetically modified yeast host cell of claim 6 , further comprising a heterologous nucleic acid encoding an enzyme that can convert isopentenyl pyrophosphate (IPP) into dimethylallyl pyrophosphate (DMAPP).

19. The genetically modified yeast host cell of claim 6 , further comprising a heterologous nucleic acid encoding an enzyme that can condense IPP and/or DMAPP molecules to form a polyprenyl compound.

20. The genetically modified yeast host cell of claim 6 , further comprising a heterologous nucleic acid encoding an enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound.

21. The genetically modified yeast host cell of claim 20 , wherein the enzyme that can modify IPP or a polyprenyl to form an isoprenoid compound is selected from the group consisting of carene synthase, geraniol synthase, linalool synthase, limonene synthase, myrcene synthase, ocimene synthase, α-pinene synthase, β-pinene synthase, γ-terpinene synthase, terpinolene synthase, amorphadiene synthase, α-farnesene synthase, β-farnesene synthase, farnesol synthase, nerolidol synthase, patchouliol synthase, nootkatone synthase, and abietadiene synthase.

22. The genetically modified yeast host cell of claim 1 , wherein the isoprenoid is selected from the group consisting of a hemiterpene, monoterpene, diterpene, triterpene, tetraterpene, sesquiterpene, and polyterpene.

23. The genetically modified yeast host cell of claim 1 , wherein the isoprenoid is a C 5 -C 20 isoprenoid.

24. The genetically modified yeast host cell of claim 1 , wherein the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, α-farnesene, β-farnesene, farnesol, geraniol, geranylgeraniol, isoprene, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β-pinene, sabinene, γ-terpinene, terpinolene, and valencene.

25. The genetically modified yeast host cell of claim 1 , wherein the genetically modified yeast host cell is Saccharomyces cerevisiae.

26. A method for producing an isoprenoid comprising:

(a) culturing a population of the genetically modified yeast host cell of claim 1 in a medium with a carbon source under conditions suitable for making said isoprenoid compound; and

(b) recovering said isoprenoid compound from the medium.

27. A method for increasing the production of acetyl-CoA or an acetyl-CoA derived compound in a yeast host cell, the method comprising:

(a) expressing in the yeast host cell a heterologous nucleic acid encoding a phosphoketolase (PK; EC 4.1.2.9);

(b) expressing in the yeast host cell a heterologous nucleic acid encoding a phosphotransacetylase (PTA; EC 2.3.1.8); and

(c) functionally disrupting an endogenous glycerol-1-phosphatase enzyme (EC 3.1.3.21) that converts acetyl phosphate to acetate,

wherein the genetically modified yeast host cell produces an increased amount of acetyl-CoA or an acetyl-CoA derived compound compared to yeast cells which are not genetically modified in the same way.

28. The method of claim 27 , wherein the glycerol-1-phosphatase is selected from GPP1/RHR2, GPP2/HOR2, and homologues and variants thereof.

29. The method of claim 28 , wherein GPP1/RHR2, or a homologue or variant thereof, is functionally disrupted.

30. The method of claim 28 , wherein GPP2/HOR2, or a homologue or variant thereof, is functionally disrupted.

31. The method of claim 28 , wherein both GPP1/RHR2 and GPP2/HOR2, or both a homologue or variant of GPP1/RHR2 and a homologue or variant of GPP2/HOR2, are functionally disrupted.

32. The method of claim 27 , wherein the yeast host cell is Saccharomyces cerevisiae.

Assignments (14)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2023
From: TOTALENERGIES RAFFINAGE CHIMIE
To: TOTALENERGIES ONETECH
Reel/Frame 063941/0503 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062760/0753 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2023
From: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
To: AMYRIS, INC.
Reel/Frame 062760/0818 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
GRANT OF PATENT SECURITY INTEREST Recorded Nov 20, 2019
From: AMYRIS, INC.
To: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
Reel/Frame 051072/0310 →
RELEASE OF SECURITY INTEREST Recorded Aug 28, 2019
From: STEGODON CORPORATION
To: AMYRIS, INC.
Reel/Frame 050206/0606 →
SECURITY INTEREST Recorded Aug 16, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 050081/0106 →
SECURITY INTEREST Recorded Jun 16, 2016
From: HERCULES CAPITAL INC.
To: STEGODON CORPORATION
Reel/Frame 039048/0251 →
SECURITY INTEREST Recorded Jun 3, 2016
From: AMYRIS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 038878/0381 →
ASSIGNMENT OF JOINT INTEREST WITH ASSIGNOR Recorded Sep 25, 2014
From: AMYRIS, INC.
To: TOTAL MARKETING SERVICES
Reel/Frame 033824/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2014
From: HAWKINS, KRISTY MICHELLE; MAHATDEJKUL-MEADOWS, TINA TIPAWAN; MEADOWS, ADAM LEON; PICKENS, LAUREN BARBARA; TAI, ANNA; TSONG, ANNIE ENING
To: AMYRIS, INC.
Reel/Frame 032517/0908 →